{bio,medical} informatics
bookmark:
connotea
::
del.icio.us
::digg
::furl
::reddit
::yahoo::
The New York Times
Lion Bioscience Seeking U.S. Acquisitions[requires 'free' registration]
"Lion Bioscience A.G., the German biotechnology company, said it was looking for acquisitions and partnership opportunities in the United States to add to a partnership it announced yesterday with Celera Genomics."
"Klaus Sprockamp, the chief financial officer of Lion, said he had been meeting this week with companies that Lion may acquire; he declined to identify them. Any purchases would be paid for in stock, specifically the American depository receipts the company issued on the Nasdaq exchange earlier this year. "That's the main purpose of our Nasdaq listing," Mr. Sprockamp said."
"Celera Genomics Corp., the Rockville company famed for its development of genetic databases, will announce a deal this morning with a German company to bring new analytical software to the desktops of biologists.
The deal, with Lion Bioscience AG of Heidelberg, means that three popular software programs developed by Lion will be made available over the next few months to academic and drug-company biologists who subscribe to Celera's databases. In addition, the two companies will work together to develop more analytical tools.
Peter Barrett, Celera's executive vice president and chief business officer, said the deal is a sign that the company is open to collaborations with other firms that can help make its gene databases more useful.
"We don't have the mentality that we have to build everything on our own," he said in an interview. "We're going to work together with Lion to . . . define what the market needs are.""
"With a new Celera alliance in its clutches, Lion Biosciences is poised to become king of the bioinformatics jungle, analysts said Thursday.
“Celera’s use of Lion’s product is a validation of Lion’s bioinformatics capabilities,” said Winton Gibbons, an analyst at William Blair. “It’s a little bit of a coup.”"
“It’s hard to predict whether companies will be increasingly ‘gobbled up,’ especially with venture capital’s friendlier attitude towards biotechnology-related companies lately,” said Justin Saeks, an analyst for Drug Discovery Technologies at Frost & Sullivan.
But in order to avoid getting gobbled up, bioinformatics companies are going to have to form alliances with content providers like Celera, said Gibbons.
“You need to have more than bioinformatics to succeed,” Gibbons said. Since Celera and similar companies provide some bioinformatics tools to its subscribers free, a software provider who is not allied with content provider is “trying to sell something that people could get for free with the content.”"
[ rhetoric ]
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”
BIOINFORMATICS IN THE 21st CENTURY[ search ]
[ outbound ]
biospace
/
genomeweb
/
bio-it world
/
scitechdaily
/
biomedcentral
/
the panda's thumb
/
bioinformatics.org
/
nodalpoint
/
flags and lollipops
/
on genetics
/
a bioinformatics blog
/
andrew dalke
/
the struggling grad student
/
in the pipeline
/
gene expression
/
free association
/
pharyngula
/
the personal genome
/
genetics and public health blog
/
the medical informatics weblog
/
linuxmednews
/
nanodot
/
complexity digest
/
eyeforpharma
/
nsu
/
nyt science
/
bbc scitech
/
newshub
/
biology news net
/
informatics review
/
stanford
/
bmj info in practice
/
bmj info in practice
/
[ schwag ]
look snazzy and support the site at the same time by buying some snowdeal schwag !
[ et cetera ]
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III
.
© 2000-2005